Use of a Pulmonary Artery Pressure Sensor to Manage Patients With Left Ventricular Assist Devices.

Autor:	Thohan V; Mission Heart HCA HealthCare, Asheville, NC (V.T.)., Abraham J; Center for Cardiovascular Analytics, Research, and Data Science, Providence Heart Institute, Providence St. Joseph Health, Portland, OR (J.A.)., Burdorf A; University of Nebraska Medical Center, Omaha (A.B.)., Sulemanjee N; Advocate Aurora Medical Group, St. Luke's Medical Center, Milwaukee, WI (N.S.)., Jaski B; San Diego Cardiac Center, CA (B.J.)., Guglin M; Indiana University School of Medicine, Krannert Institute of Cardiology, Indianapolis (M.G.)., Pagani FD; University of Michigan, Ann Arbor (F.D.P.)., Vidula H; University of Pennsylvania, Philadelphia (H.V.)., Majure DT; Weill Cornell Medicine, Division of Cardiology, New York (D.T.M.)., Napier R; Prisma Health, Columbia, SC (R.N.)., Heywood TJ; Scripps Health, La Jolla, CA (T.J.H.)., Cogswell R; Department of Medicine, Division of Cardiology, University of Minnesota, Minneapolis (R.C.)., Dirckx N; Abbott Inc, Abbott Park, IL (N.D., D.J.F.)., Farrar DJ; Abbott Inc, Abbott Park, IL (N.D., D.J.F.)., Drakos SG; Division of Cardiovascular Medicine & Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah Health and School of Medicine, Salt Lake City (S.G.D.).
Jazyk:	angličtina
Zdroj:	Circulation. Heart failure [Circ Heart Fail] 2023 Jun; Vol. 16 (6), pp. e009960. Date of Electronic Publication: 2023 Apr 20.
DOI:	10.1161/CIRCHEARTFAILURE.122.009960
Abstrakt:	Background: Hemodynamic-guided management with a pulmonary artery pressure sensor (CardioMEMS) is effective in reducing heart failure hospitalization in patients with chronic heart failure. This study aims to determine the feasibility and clinical utility of the CardioMEMS heart failure system to manage patients supported with left ventricular assist devices (LVADs). Methods: In this multicenter prospective study, we followed patients with HeartMate II (n=52) or HeartMate 3 (n=49) LVADs and with CardioMEMS PA Sensors and measured pulmonary artery pressure, 6-minute walk distance, quality of life (EQ-5D-5 L scores), and heart failure hospitalization rates through 6 months. Patients were stratified as responders (R) and nonresponders to reductions in pulmonary artery diastolic pressure (PAD). Results: There were significant reductions in PAD from baseline to 6 months in R (21.5-16.5 mm Hg; P <0.001), compared with an increase in NR (18.0-20.3; P =0.002), and there was a significant increase in 6-minute walk distance among R (266 versus 322 meters; P =0.025) compared with no change in nonresponder. Patients who maintained PAD <20 compared with PAD ≥20 mm Hg for more than half the time throughout the study (averaging 15.6 versus 23.3 mm Hg) had a statistically significant lower rate of heart failure hospitalization (12.0% versus 38.9%; P =0.005). Conclusions: Patients with LVAD managed with CardioMEMS with a significant reduction in PAD at 6 months showed improvements in 6-minute walk distance. Maintaining PAD <20 mm Hg was associated with fewer heart failure hospitalizations. Hemodynamic-guided management of patients with LVAD with CardioMEMS is feasible and may result in functional and clinical benefits. Prospective evaluation of ambulatory hemodynamic management in patients with LVAD is warranted. Registration: URL: https://www. Clinicaltrials: gov; Unique identifier: NCT03247829. Competing Interests: Disclosures Dr Thohan is a consultant for Abbott, Impulse Dynamics, and Battelle and participated in Speaker’s Bureau for Pfizer and Boehringer Ingelheim. Dr Abraham is a consultant for Abbott and Abiomed. A. Burdorf participated in Speaker’s Bureau for Abbott. Dr Pagani works for Scientific Advisory Board for FineHeart Inc. Dr Vidula received research grant funding from Abbott and is supported by National Institutes of Health (NIH) grant 1R01HL155201-01. Dr Heywood received Speaker’s Honoraria and research support from Abbott. Dr Cogswell received Speaker’s Honoraria for Abbott. He is third party employed at Medtronic (spouse). N. Dirckx and Dr Farrar are Abbott Employees. Dr Drakos is a consultant for Abbott. He received research support from Novartis, Merck, NIH, American Heart Association, Department of Veterans Affairs, and Nora Eccles Treadwell Foundation. The other authors report no conflicts.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu